AstraZeneca Pharma India Limited has submitted a mandatory compliance certificate to the BSE and NSE. The certificate, issued by the Registrar and Transfer Agent (RTA), Integrated Registry Management Services Private Limited, confirms adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This confirmation covers the period from February 1, 2026, to February 28, 2026, specifically regarding the dematerialization of securities.
Mandatory Regulatory Filing Submitted
AstraZeneca Pharma India Limited formally communicated to the stock exchanges, including the BSE Limited and the National Stock Exchange of India Ltd., regarding a crucial regulatory requirement. The communication, dated March 13, 2026, encloses the necessary certificate confirming compliance with the Depositories and Participants Regulations.
Details of the RTA Certificate
The core of the filing is the certificate dated March 3, 2026, provided by Integrated Registry Management Services Private Limited, acting as the Registrar and Transfer Agent (RTA). This document specifically addresses compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The covered reporting period for this confirmation is February 01, 2026, to February 28, 2026.
Confirmed Actions for Dematerialization
The RTA confirmed that within 15 days of receiving security certificates for dematerialization from the depository participant, the following actions were successfully executed:
- Securities comprised in the certificates were successfully Dematerialized and are listed on the relevant stock exchange(s).
- Any mutilated and canceled security certificates forwarded by participants were processed.
- The name of the depository was substituted as the registered owner in the company’s records.
The document was signed by Tanya Sanish, Company Secretary & Compliance Officer, confirming the successful completion of these obligations.
Source: BSE
